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X-linked lymphoproliferative (XLP) disease is 
a complex disorder characterized by severe im-
mune dysregulation that is exacerbated by EBV 
infection, often resulting in fatal infectious 
mononucleosis (1). Individuals with XLP who 
survive EBV infection frequently develop dys-
gammaglobulinemia and B cell lymphomas. The 
presence of these phenotypes in XLP patients 
in the absence of EBV exposure, however, sug-
gests a more basic immune dysfunction associated 
with this disease.
Genetic studies have demonstrated that 
XLP is associated with mutations aff  ecting 
SH2D1A/SAP/DSHP, which encodes a 128–
amino acid protein comprised largely of an SH2 
domain (hereafter referred to as signal lympho-
cyte activation molecule [SLAM]-  associated 
protein [SAP]) (1). SAP is expressed in T cells, 
NK cells, NKT cells, and some B cell popu-
lations. SAP binds to a conserved tyrosine-
containing motif found in the intracellular domain 
of CD150/SLAM and related family members, 
including CD84, CD229/Ly9, CD224/2B4, 
CRACC, and NTB-A/Ly108 (1). After liga-
tion of SLAM-related receptors, SAP recruits 
and activates the Src family kinase Fyn, thereby 
permitting receptor tyrosine phosphorylation 
and binding of several downstream proteins 
(2–4). Overexpression studies indicate that SAP 
may also competitively interfere with recruit-
ment of phosphatases (5, 6).
To provide insight into the pathophysiology 
of XLP, several groups have generated mice 
that lack SAP expression (7–9). Studies of these 
mice and XLP patients demonstrated that SAP 
is involved in a diverse array of lymphocyte 
functions, including Th cell signaling and dif-
ferentiation, 2B4-mediated NK and CD8 cell 
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collaboration by mechanisms that are distinct from its role in cytokine regulation.
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killing, generation of NKT cells, and germinal center (GC) 
formation, as well as the generation of memory B cells and 
long-lived plasma cells (1). Initial examination of SAP−/− 
mice suggested that SAP expression is critical for CD4 
T cell–mediated help necessary for regulating long-term 
  humoral immunity to lymphocytic choriomeningitis virus 
(LCMV) (10). However, more recent data argue that B cells 
also contribute to defects in humoral immunity (11, 12). 
Thus, the factors leading to humoral defects associated with 
SAP defi  ciency remain poorly understood.
In this paper, we have further examined immune re-
sponses in SAP−/− mice. We demonstrate that SAP−/− mice 
can mount a normal T-independent response to 4-hydroxy-
3-nitrophenylacetyl (NP)-LPS but show impaired B cell pro-
liferation in addition to defective GC formation in response 
to T-dependent antigens. These defects are largely T cell de-
pendent because transfer of WT, but not SAP-defi  cient, CD4 
cells into SAP−/− or RAG2−/− reconstituted hosts markedly 
improved defects in B cell proliferation, GC formation, and 
antibody titers.
To identify defects that contribute to the impaired hu-
moral responses in SAP−/− mice, we assessed CD4 T cell 
functions. Although SAP-defi  cient CD4 cells have defective 
TCR-mediated Th2 cytokine production in vitro (7, 8, 13), 
we provide evidence using in vivo challenge with a robust 
Th2 inducing agent, as well as transfer of in vitro–polarized 
cells, that the humoral defects can be separated from the cy-
tokine production defects. In contrast, we observed defective 
regulation of both inducible costimulator (ICOS) and CD40L 
(CD154), two critical regulators of GC formation. Using ret-
roviral reconstitution with WT and mutant forms of SAP, we 
demonstrate that in contrast to cytokine defects, the regula-
tion of ICOS and CD40L expression as well as long-term 
humoral defects in SAP−/− mice can be rescued by retroviral 
reconstitution with either SAP or SAP-R78A, a mutant 
  previously shown to prevent SAP-mediated recruitment of 
Fyn to SLAM. Consistent with these observations, we also 
demonstrate that Fyn−/− mice can form GCs and develop 
  antibody responses to immunization. Finally, we provide 
  evidence that SLAM/SAP-mediated pathways help regulate 
early surface CD40L (sCD40L) expression. Our results dem-
onstrate that SAP defi  ciency aff  ects the expression of key 
molecules required for T cell–mediated B cell help and sug-
gest that the humoral defects in SAP−/− mice occur by 
mechanisms that are at least partially independent of SAP’s 
regulation of cytokine production.
RESULTS
SAP−/− mice exhibit abnormalities in T-dependent 
immune responses
SAP is expressed in T, NK, NKT, and some B cells including 
human GC B cells (12, 14, 15). Although initial adoptive 
transferred data indicated a T cell–intrinsic defect in long-
term humoral immunity (10), recent data using a cell transfer 
model into RAG2−/− mice argued that SAP-defi  cient B cells 
are also defective (11, 12). To further examine these issues, 
SAP−/− mice were immunized with the T-independent anti-
gen, NP-LPS. Consistent with data using NP-Ficoll (16), 
SAP−/− mice mounted a normal T-independent response 
(Fig. 1 A). In addition, SAP-defi  cient B cells proliferated 
comparably to WT B cells when stimulated with anti-CD40, 
LPS, or anti-IgM in vitro (not depicted). Similar fi  ndings have 
been reported for B cells isolated from XLP patients (17).
To evaluate the nature of the humoral defect in greater 
detail, WT and SAP−/− mice were immunized with a de-
fi  ned T-dependent antigen, NP-KLH, or a complex antigen, 
sheep red blood cells (SRBCs), and formation of GCs and 
antibody production were determined during primary and 
secondary responses (Fig. 1 B and Fig. S1, which is available 
at http://www.jem.org/cgi/content/full/jem.20052097/
DC1). After immunization, B cells down-regulate IgD and 
express activation markers including Fas. A small fraction of 
precursor B cells within the follicles will up-regulate diff  er-
entiation markers including PNA and GL-7, down-regulate 
CD38, and undergo a rapid clonal expansion, forming GCs. 
Accordingly, in WT mice we observed GC staining after 4 d 
and maximal GC development by 8–9 d after NP-KLH 
  immunization (Fig. 1 C). SAP−/− mice, however, showed 
dramatic defects in GC development after both primary and 
secondary immunization (Fig. 1 C). Similar results were ob-
served by examining the B220+IgDloFashi B cells for peanut 
agglutinin (PNA)hi and CD38int expression as well as in re-
sponse to SRBCs (not depicted and Fig. S1). Thus, SAP-de-
fi  cient B cells fail to diff  erentiate into GCs during a robust 
T-dependent response.
Although NP-specifi  c IgM levels were similar in WT and 
SAP−/− mice, NP-specifi  c total IgG levels were 5–50-fold 
lower in SAP−/− mice relative to WT (Fig. 1 D). The reduc-
tion in IgG1 was most dramatic: SAP−/− mice had 10–100-
fold lower levels in the primary and 1,000–100,000-fold 
lower levels in the secondary response. Levels of NP-specifi  c 
IgG3 were less aff  ected, consistent with extrafollicular diff  er-
entiation of IgG3-producing cells. Intermediate level defects 
were observed for IgG2a and IgG2b. Despite the lack of de-
tectible GC development, SAP−/− mice were able to pro-
duce high affi   nity antibodies as indicated by reactivity with 
[NP-(3)] (not depicted) and increased antibody titres in re-
sponses to secondary challenge, although most isotype titres 
were still far below those of WT mice (Fig. 1 D). Consistent 
with these observations, we observed dramatic defects in 
numbers of long-term antibody-secreting cells in the bone 
marrow (not depicted and see Fig. 4 C).
To examine the impaired humoral responses in SAP−/− 
mice in greater detail, animals were immunized with SRBCs 
and GC formation and cell proliferation were assessed. 
  Notably, although SAP-defi  cient splenic CD4 cells prolif-
erated similarly to WT cells after immunization, marked 
  reductions in splenic B cell proliferation were observed in 
SAP−/− mice (Fig. 1 E) in addition to the GC formation 
defects (Fig. S1). These proliferation defects were present by 
day 4, but most dramatic by day 8. Thus, SAP-defi  cient B 
cells display defects in proliferation as well as diff  erentiation.JEM VOL. 203, June 12, 2006  1553
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Figure 1.  SAP−/− mice exhibit impaired immune responses to 
T-  dependent antigens. (A) Production of NP-specifi  c antibodies 21 d after 
NP-LPS (T-independent) immunization by ELISA. (B) Mice were immunized with 
a T-dependent antigen (NP-KLH) and challenged 70 d after primary immuniza-
tion (n = 4–5 mice/time point/group). (C) GC development evaluated by gating 
on B220+IgDlo cells: GC B cells are FashiGL-7hi. (D) NP-specifi  c [NP-(30)] antibody 
detected by ELISA. Ribi refers to adjuvant control. Day 0 of secondary response is 
70 d after primary immunization. Note that y-axis NP-specifi  c antibody dilution 
refers to the midpoint of the dilution curve for each genotype. Axes for each 
isotype are different. (E) Mice were immunized with SRBCs (Fig. S1) and injected 
with BrdU 5 h before they were killed. The numbers of dividing splenic CD19+ 
B cells and CD4+ T cells were determined by staining with anti-BrdU antibody.1554  REGULATION OF HUMORAL IMMUNITY BY SAP | Cannons et al.
Figure 2.  WT CD4 cells rescued antibody production in RAG2−/− 
recipients. RAG2−/− reconstitution experiments: SAP-defi  cient or WT 
CD4 T cells and either WT B cells (left panels A, C, E, and F) or SAP-
 defi  cient B cells (right panels B, D, G, and H) were cotransferred into RAG2−/− 
hosts (n = 4 mice/time point/group). Note that transfer experiments with 
WT or SAP-defi  cient B cells are separate experiments (see Fig. S3 for direct 
comparison). (A and B) GC development assessed by gating on B220+IgDlo 
cells and staining for FashiGL-7hi cells. (C and D) SRBC-specifi  c antibody 
response evaluated by ELISA. Nonimmunized control refers to mice that 
received T and B lymphocytes but were not immunized. (E and G) Mice 
were injected with BrdU 5 h before they were killed to assess CD19+ B cell 
and CD4+ T cell proliferation. (F and H) Total bone marrow IgG+ plasma 
cells (ASC) on day 25 were quantifi  ed by ELISPOT.JEM VOL. 203, June 12, 2006  1555
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Rescue of Ig production by WT CD4 cells
The profound defects in T-dependent responses in SAP−/− 
mice support previous data arguing that a major component of 
their humoral defects to LCMV lies in T cells (10). To further 
address this issue, either WT or SAP-defi  cient OT-II transgenic 
(OVA-specifi  c) CD4 cells were transferred into SAP−/− hosts 
and immunized with NP-OVA. WT OT-II and SAP−/− OT-II 
CD4 cells proliferated equivalently as assessed via CFSE dilution 
(Fig. S2 A, available at http://www.jem.org/cgi/content/full/
jem.20052097/DC1), consistent with our BrdU analyses (Fig. 
1 E). However, only WT OT-II cells supported effi   cient antigen-
specifi  c antibody production in the SAP−/− host (Fig. S2 B).
To clarify T verses B cell contributions to the humoral de-
fects, either WT or SAP-defi  cient naive CD4 cells were adop-
tively transferred in conjunction with either SAP-  defi  cient or 
WT B cells into RAG2−/− hosts, which were permitted to 
equilibrate 30 d after transfer to avoid eff  ects of homeostatic 
proliferation. Before immunization, mice were assessed for 
equivalent cell transfer, cell survival, and baseline serum anti-
body levels. Interestingly, when WT CD4 T cells were trans-
ferred along with either SAP-defi  cient or WT B cells, GC 
diff  erentiation markers were observed in the RAG2−/− mice 
before immunization (Fig. 2, A and B, Day 0, and Fig. S3 A, 
which is available at http://www.jem.org/cgi/content/full/
jem.20052097/DC1). After SRBC immunization, mice 
  reconstituted with WT CD4 cells displayed a robust increase 
in the expression of GC markers (Fig. 2, A and B, top, and Fig. 
S3 A) accompanied by B cell proliferation (Fig. 2, E and G) 
and antibody production (Fig. 2, C and D, and Fig. S3 B). 
However, transfer of SAP-defi  cient CD4 T cells in conjunc-
tion with either SAP-defi  cient or WT B cells failed to result in 
GC development, high antibody titers, or the development of 
long-lived plasma cells (Fig. 2, A–D, F, and H). Moreover, 
proliferation of either WT or SAP-defi  cient B cells was mark-
edly impaired in the presence of SAP-defi  cient CD4 cells (Fig. 
2, E and G), strongly supporting our hypothesis that the B cell 
proliferation defect is due to impaired T cell–mediated B cell 
help. In contrast to a previous study (11), we did not observe a 
substantial B cell component to the humoral defects under 
these conditions (Fig. 2 and Fig. S3). Thus, WT CD4 T cells 
can rescue many of the humoral defects in SAP−/− mice.
Impaired GC formation and antibody production 
during a Th2 response
CD4 T cells produce cytokines such as IL-4, IL-10, and IL- 21 
that help promote GC formation and antibody secretion. 
In vitro, SAP-defi  cient T cells demonstrate impaired TCR-
  induced Th2 cytokine production yet respond normally to polar-
izing cytokines (7, 8, 13). These data, in conjunction with low 
IgE levels in SAP−/− mice, suggest that Th2 defects contribute 
to their humoral defects. To investigate this issue, we chal-
lenged SAP−/− mice with eggs from Schistosoma mansoni, a hel-
minth that induces a strong Th2 response. Upon i.v. injection, 
these eggs lodge in the lungs and induce a robust eosinophilic 
granuloma response as well as the production of Th2 cytokines 
from multiple cell types (18). Consistent with the normal 
  responses of SAP-defi   cient T cells to polarizing cytokines 
in vitro (7, 8, 13), WT and SAP−/− mice   responded equally to 
this agent with respect to granuloma size and content (Fig. 3, A 
and B). Furthermore, CD4 cells from the draining lymph nodes 
of both WT and SAP−/− mice produced IL-4, IL-5, IL-10, 
and IL-13 in response to a schistosome egg antigen (SEA) para-
site preparation (Fig. 3 C and not depicted). SAP-defi  cient 
splenic CD4 cells stimulated with SEA also produced and se-
creted Th2 cytokines, albeit at lower levels than WT cells.
Despite the production of Th2 cytokines in mice chal-
lenged with S. mansoni eggs, SAP−/− mice failed to develop 
GCs in the spleen and draining lymph node as evaluated by 
Fashi CD38int expression (Fig. 3 D). In addition, although 
SAP−/− mice had relatively normal SEA-specifi  c IgM and 
only slightly reduced IgG3, they failed to secrete SEA-spe-
cifi  c IgG1, IgG2b, and IgE isotypes (Fig. 3 E). Although, 
IgG2a levels were intermediate, these levels were quite low 
even in WT mice, consistent with the Th2 response. Thus, 
SAP−/− mice are unable to produce eff  ective antibody titres 
even in the presence of Th2 cytokine production.
Nonetheless, although SAP-defi   cient T cells secreted 
Th2 cytokines when challenged in vivo with S. mansoni, they 
still produced elevated IFN-γ as compared with WT cells 
(Fig. 3 C and not depicted). To address whether an imbal-
ance in Th cytokine production or inappropriate kinetics 
and/or levels of cytokines infl  uenced B cell activation and 
diff  erentiation in these mice, WT and SAP-defi  cient OT-II 
CD4 cells were polarized into either Th1 (IFN-γ–secreting) 
or Th2 (IL-4–, IL-5–, and IL-10–secreting) cells in vitro and 
transferred into SAP−/− hosts. As demonstrated previously, 
both WT and SAP-defi  cient cells polarized equivalently 
upon exposure to cytokines in vitro (references 7, 8, and 13, 
and not depicted). After NP-OVA immunization, WT OT-
II–diff  erentiated Th1 and Th2 CD4 cells provided B cell 
help, exemplifi  ed by the production of NP-specifi  c antibod-
ies (Fig. 4 A), GC formation (Fig. 4 B), and development of 
long-lived bone marrow plasma cells (Fig. 4 C). However, 
both the SAP-defi  cient Th1 and Th2 OT-II cells failed to 
induce humoral responses (Fig. 4). Thus, neither a defect in 
Th2 cytokine production nor an imbalance in Th1/Th2 dif-
ferentiation is exclusively responsible for the humoral defects 
observed in SAP−/− mice.
Elevated and prolonged expression of CD40L
Another integral function of CD4-mediated B cell help is the 
expression of activation markers, including CD40L, OX40, 
and ICOS. CD40L is a critical activation marker required for 
B cell Ig class switching and GC formation, mutations of 
which cause the X-linked hyper-IgM syndrome (19). How-
ever, overexpression of CD40L and/or prolonged stimulation 
of CD40 on B cells can also impair GC formation and pro-
mote early plasma cell diff  erentiation (20, 21). To monitor 
the expression of activation markers, naive AND TCR trans-
genic CD4 cells were stimulated with pigeon cytochrome-c 
(PCC)-pulsed P13.9 APCs. CD40L has a complex pattern of 
expression characterized by both early and late phases (22, 23). 1556  REGULATION OF HUMORAL IMMUNITY BY SAP | Cannons et al.
Within 6 h of stimulation, approximately one third of 
WT AND CD4 cells expressed sCD40L, which was down-
  regulated 6–12 h after stimulation and subsequently reex-
pressed at lower levels at 48 h (Fig. 5, A and B). Surprisingly, 
SAP-defi  cient AND cells exhibited a marked increase in the 
number and intensity of cells expressing sCD40L. Although 
sCD40L levels were decreased after 6 h, they were maintained 
at exaggerated levels on SAP-defi  cient cells throughout the 
entire duration of the time course examined (Fig. 5, A and B, 
and Fig. S4, which is available at http://www.jem.org/cgi/
content/full/jem.20052097/DC1). Increased expression of 
CD40L was observed at the mRNA level. SAP-defi  cient cells 
both showed elevated CD40L mRNA at baseline and failed 
to down-regulate it upon activation (Fig. 5, C and D). This 
elevated expression pattern was specifi  c to CD40L, as other 
activation markers, such as CD69, SLAM, OX40, and 
CXCR5, were expressed at levels and kinetics comparable to 
WT cells (Fig. 5 B and not depicted). Similar results were ob-
served using OT-II CD4 cells stimulated with peptide-pulsed 
dendritic cells and nontransgenic CD4 cells stimulated with 
anti-CD3 plus anti-CD28 (not depicted).
SLAM/SAP-dependent mechanisms of T cell–mediated 
B cell help
SLAM is up-regulated on activated T cells and is expressed 
constitutively on B cells, macrophages, and dendritic cells (1). 
Figure 3.  Impaired humoral immunity in response to S. mansoni 
egg injection. (A) Giemsa-stained lung section: granuloma formation 8 d 
after secondary injection. (B) Granuloma volume and percent eosinophil 
content. (C) Pooled mediastinal lymph nodes or splenocytes were cultured 
with 20 μg SEA for 72 h. For intracellular cytokine analysis, cells were 
rested for 18 h and restimulated with 3 ng/ml PMA and 1 μg/ml 
  ionomycin. (D) Lymph nodes and splenocytes were stained for GC markers 
by gating on B220+IgDlo cells: GC B cells are FashiCD38int. (E) SEA-specifi  c 
antibodies evaluated 8 d after challenge with S. mansoni eggs by ELISA. 
Note the different scales of the axes. *, antibody levels not detected. Data 
represent one of two independent experiments (n = 5 mice/group).JEM VOL. 203, June 12, 2006  1557
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Figure 4.  SAP-defi  cient Th2-differentiated antigen-specifi  c CD4 
T cells fail to rescue humoral defects. Th1- or Th2-skewed WT OT-II and 
SAP−/− OT-II CD4 cells were adoptively transferred to SAP−/− hosts that 
were subsequently immunized with NP-OVA. WT and SAP−/− controls 
did not receive transferred cells but were immunized. Data represent one 
of three independent experiments (n = 3–4 mice/time point/group). 
(A) [NP-(30)]-specifi  c antibodies detected 32 d after immunization by 
ELISA. (B) GCs were detected in SAP−/− hosts reconstituted with WT but 
not SAP-defi  cient OT-II cells via staining with IgD (red) and GL-7 (green) 
10 d after immunization. (C) Total bone marrow IgG+ plasma cells (ASC) 
were quantifi  ed by ELISPOT.
SLAM interacts homophilically and plays a role in T cell acti-
vation (1, 13, 24, 25). To evaluate if SLAM–SLAM interac-
tions could infl  uence T cell–mediated B cell help, a variant of 
the P13.9 fi  broblast surrogate APC line that expresses SLAM 
(13) was used to stimulate AND CD4 cells. Expression of 
SLAM on the APCs reduced the kinetics and expression of 
sCD40L on WT CD4 cells at early times after stimulation 
(Fig. 5 E), but it did not aff  ect later surface levels (not depicted) 
or CD40L mRNA levels (Fig. 5 F). Moreover, expression of 
SLAM on the APCs had no impact on the kinetics or duration 
of sCD40L expression on SAP-defi  cient cells (Fig. 5 E). Ex-
pression of other activation markers including SLAM and 
CXCR5 on either WT or SAP-defi  cient CD4 cells was also 
unaff  ected by SLAM (not depicted). These results indicate that 
SAP expression and SLAM engagement potentially contribute 
to the tight regulation of early sCD40L expression.
Delayed and impaired ICOS expression
Another T cell activation marker that has an important 
role in enhancing T cell–dependent B cell help is ICOS, 
which is induced rapidly on T cells after TCR engage-
ment. WT AND CD4 cells stimulated with peptide-pulsed 
APCs showed a  rapid increase in ICOS expression. 
Although SAP-defi  cient T cells induced surface expres-
sion of ICOS, the kinetics of induction and maximal in-
tensity of expression were considerably diminished (Fig. 6, 
A and B). Impaired ICOS expression was also observed 
with low peptide concentrations (not depicted) as well as 
when OT-II cells were stimulated with peptide-pulsed 
dendritic cells (not depicted). However, unlike CD40L, 
expression of SLAM on the APCs had no noticeable impact 
on ICOS up-regulation on either WT or SAP-defi  cient 
CD4 cells (Fig. S5, available at http://www.jem.org/cgi/1558  REGULATION OF HUMORAL IMMUNITY BY SAP | Cannons et al.
content/full/jem.20052097/DC1). These results suggest 
that some SAP-mediated phenotypes contributing to im-
paired B cells are SLAM independent.
T cells from XLP patients also show reduced ICOS ex-
pression in vitro (17). To evaluate if these defects are ob-
served in vivo, CFSE-labeled WT and SAP-defi  cient OT-II 
Figure 5.  Heightened and sustained CD40L surface expression on 
SAP-defi  cient CD4 cells. (A–C) WT and SAP−/− AND CD4 cells were 
stimulated with peptide-pulsed (1,000 nM PCC) P13.9 cells and evaluated 
for activation markers. (A) SAP−/− AND cell display enhanced and sus-
tained levels of CD40L. (B) Percentage of Vα11+CD4+ cells stained for 
CD40L (left) and SLAM (right) expression. Mean fl  uorescence intensity 
for CD40L and SLAM are shown in Fig. S4. (C and D) SAP-deficient 
cells display elevated CD40L mRNA. RNA was isolated from WT and SAP-
 defi  cient AND CD4 cells after stimulation with peptide-pulsed P13.9 APCs 
and subjected to (C) real-time quantitative PCR and (D) RT-PCR analysis. 
(E) SLAM expression on P13.9 APCs reduced expression of CD40L on WT 
AND cells. (F) SLAM expression on P13.9 APCs did not affect mRNA levels 
after stimulation as assessed by RT-PCR.JEM VOL. 203, June 12, 2006  1559
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Figure 6.  Impaired ICOS expression on SAP-defi  cient CD4 cells in 
vitro and in vivo. (A–C) WT and SAP−/−AND CD4 cells were stimulated 
with peptide-pulsed (1,000 nM PCC) P13.9 cells and evaluated for ICOS 
expression. (A) Expression and kinetics of ICOS measured by fl  ow cytom-
etry. (B) Percentage of Vα11+CD4+ cells stained positive for ICOS expres-
sion and mean fluorescence intensity of ICOS. (C) CFSE-labeled WT 
OT-II or SAP−/− OT-II T cells were adoptively transferred to SAP−/− hosts 
that were subsequently immunized with either PBS control or NP-OVA. 
Data represent one of three independent experiments (n = 2 mice/group). 
One representative example is shown for each genotype. Labeled cells 
were evaluated for expression of SLAM and ICOS 2 d after immunization.
CD4 cells were adoptively transferred into SAP−/− recipi-
ents. 2 d after NP-OVA immunization, both WT and SAP-
defi  cient OT-II had divided as assessed by CFSE dilution 
(not depicted) and up-regulated SLAM expression, indicative 
of activation (Fig. 6 C). However, SAP−/− OT-II cells dem-
onstrated impaired ICOS expression compared with WT 
OT-II CD4 cells (Fig. 6 C), verifying their defect in ICOS 
regulation in vivo.
Rescue of humoral responses by SAP independent 
of a Fyn interaction
The ability of SAP to recruit the tyrosine kinase Fyn is criti-
cal for Th2 cytokine regulation. IL-4 production can be res-
cued in SAP-defi  cient CD4 cells by reexpression of human 
SAP, but not by a SAP mutant (R78A) that exhibits de-
creased binding to the Fyn SH3 domain and fails to eff  ec-
tively recruit Fyn to SLAM (13, 25). The requirement for 
SAP in humoral responses, independent of T cell cytokine 
production, prompted us to investigate the role of SAP’s in-
teraction with Fyn. SAP, SAP-R78A, or a control (Migr) 
construct was expressed in SAP-defi  cient OT-II CD4 cells 
under neutral (anti–IFN-γ and anti–IL-4) conditions. Re-
constituted cells were transferred into SAP−/− hosts (Fig. 7, 
A and B), which were then immunized with NP-OVA to 
evaluate humoral responses. GC formation (Fig. 7, C–E), 
antibody production (Fig. 7 F), and the generation of long-
lived plasma cells (Fig. 7 G) were considerably improved 
with the transfer of either WT OT-II Migr (control vector) 
cells or SAP-defi  cient OT-II cells that expressed WT hu-
man SAP, but not SAP-defi  cient cells that expressed the 
vector control. Interestingly, SAP-defi  cient CD4 cells that 
expressed SAP-R78A also markedly improved humoral 
  responses (Fig. 7). Similar results were obtained using 
  nontransgenic T cells (not depicted). Consistent with Fyn- 
independent functions of SAP, Fyn−/− mice could respond 
to the complex T-dependent antigen (SRBCs), as exempli-
fi  ed by GC formation (Fig. 7 H) and antigen-specifi  c anti-
body production (Fig. 7 I). Thus, SAP can mediate T cell 
help for B cells by a mechanism that is less dependent on the 
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Figure 7.  GC formation and antibody responses in SAP−/− mice 
are less dependent on SAP-mediated recruitment of Fyn. (A) WT 
OT-II and SAP−/− OT-II CD4 cells were retrovirally reconstituted with Migr 
control, WT SAP, or SAP-R78A vectors and transferred to SAP−/− mice 
that were subsequently immunized with NP-OVA. Data represent three 
independent experiments (n = 3 mice/time point/group). (B) SAP expres-
sion was verifi  ed by immunoblot. (C) GC B cells were detected with the 
transfer of WT (Migr) and SAP−/− cells reconstituted with WT SAP or SAP-
R78A, but not Migr control. GC development assessed at day 8 after im-
munization by gating on B220+IgDlo cells: GC B cells are FashiGL-7hi. 
(D) Quantifi  cation of PNA+ B cells based on fl  ow cytometric analysis.(E) GCs 
were detected in SAP−/− hosts via staining with IgD (red) and GL-7 JEM VOL. 203, June 12, 2006  1561
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If misregulation of ICOS and CD40L contributes to the 
humoral defects in SAP−/− mice, one would predict that 
their regulation is also less dependent on SAP’s interaction 
with Fyn. To address this question, we introduced WT SAP, 
SAP-R78A, and vector control retroviruses into SAP−/− 
AND CD4 cells and restimulated the cells in vitro with 
  peptide-pulsed P13.9 APCs (Fig. 8 A). Reconstitution of 
SAP-defi  cient AND CD4 cells with either SAP or SAP-
R78A, but not the vector control, markedly reduced CD40L 
mRNA to levels similar to those of WT control cells, partic-
ularly upon stimulation (Fig. 8, B and C). Moreover, both 
WT SAP and SAP-R78A normalized patterns of CD40L ex-
pression as well as ICOS up-regulation (Fig. 8, D and E). 
Thus, SAP is required for both humoral immunity and Th2 
cytokine induction. However, in contrast to the cytokine de-
fects, ICOS and CD40L expression as well as long-term hu-
moral defects in SAP−/− mice can be rescued by retroviral 
reconstitution with either WT SAP or SAP-R78A, a mutant 
that does not eff  ectively recruit Fyn.
DISCUSSION
XLP is characterized by severe immune dysregulation that is 
often triggered or exacerbated by EBV infection. Evidence 
now indicates that the extreme hypersensitivity of these pa-
tients to EBV may result from defective NK and CD8 T cell 
2B4-mediated cytotoxity of EBV-infected targets (26–28). 
However, one of the other cardinal features of XLP is the 
development of dysgammaglobulinemias and, in particular, 
hypogammaglobulinemia over time. Here we provide evi-
dence supporting a strong T cell–intrinsic component to the 
humoral defects observed in SAP−/− mice and, moreover, 
show that these T cell–intrinsic defects can be separated from 
their defect in Th2 cytokine production. Furthermore, we 
demonstrate that SAP regulates CD40L and ICOS expression 
as well as humoral immunity by a mechanism that may be less 
dependent on SAP’s ability to recruit Fyn to SLAM.
Although dysgammaglobulinemias are one of the defi  n-
ing features of XLP, the mechanisms contributing to this de-
fect remain unclear. SAP−/− mice have variable decreases in 
basal antibody levels compared with WT mice (9), as well as 
humoral defects associated with impaired GC formation and 
a lack of B cell memory and long-term plasma cells (10). Re-
cent studies from XLP patients have confi  rmed a marked 
  reduction in memory (CD27+) B lymphocytes (17, 29). 
However, whether these defects are secondary to intrinsic 
B cell defects, T cell help for B cells, or both factors remains 
controversial. An initial study of SAP−/− mice suggested that 
CD4 cells were unable to provide help for long-term anti-
body production during infection with LCMV (10). However, 
more recent data using immunizations in a RAG2−/− recon-
stitution model suggested that SAP-defi  cient B cells also con-
tribute to the observed defects in antibody production (11).
In this paper, we have examined the responses of SAP−/− 
mice to immunizations and have confi  rmed that although 
T-independent responses are normal, T-dependent responses 
are defective with impaired GC development, decreased an-
tibody production, and altered patterns of class switching. 
These defects are accompanied by decreased B cell prolifera-
tion as well as diff  erentiation, perhaps accounting for the de-
creased antibody levels early after immunization. Indeed, 
these early defects in response to immunization may be more 
severe than those seen in LCMV, perhaps refl  ecting the abil-
ity of LCMV to induce a transient hypergammaglobulinemia 
(30). Nonetheless, both the humoral responses and B cell 
proliferation were markedly improved by transfer of WT, 
but not SAP-defi  cient, TCR transgenic cells, supporting our 
previous fi  ndings with LCMV (10). In addition, RAG2−/− 
reconstitution experiments confi  rm that SAP-defi  cient CD4 
cells could not provide adequate help to either WT or 
SAP−/− B cells. Furthermore, WT T cells in the presence of 
either WT or SAP-defi  cient B cells induced B cell proliferation, 
GC formation, antibody production, and long-lived bone 
marrow plasma cells. Although we cannot exclude that B 
cells contribute to these phenotypes, we have not found evi-
dence for a major B cell component, strongly supporting a 
critical role for T cells in contrast to a previous report (11).
Thus, key questions remain as to what defects are present 
in SAP-defi  cient T cells. Although SAP-defi  cient CD4 cells 
proliferate and produce IL-2 normally in response to TCR 
engagement, they do show defective TCR-induced Th2 cy-
tokine production and variable increases in IFN-γ expression 
in vitro (7, 8, 13). Interestingly, T cells from XLP patients 
have decreased production of IL-10 (17), a cytokine pro-
duced by Th2 cells that can help promote human B cell anti-
body secretion. However, despite the implication of Th2 
cytokines in the promotion of class switching and B cell help, 
we clearly demonstrate that humoral defects are still observed 
in SAP−/− mice that have Th2 responses induced by a strong 
Th2 polarizing agent, S. mansoni. Although the observation 
that SAP−/− mice can mount Th2 responses in vivo may 
seem surprising, there are multiple factors and cell types in-
volved in generating in vivo Th2 responses to S. mansoni 
(18). Nonetheless, even under these Th2-inducing condi-
tions, SAP−/− mice still fail to produce long-term humoral 
immunity to this agent. Moreover, when we artifi  cially po-
larized cells in vitro, SAP-defi  cient Th2-producing cells also 
failed to provide adequate B cell help in vivo. Thus, defective 
Th2 cytokine production cannot be the sole cause of the 
(green) 8 d after immunization. (F) [NP-(30)]-specifi  c antibodies detected 
30 d after immunization by ELISA. (G) Total bone marrow IgG+ plasma 
cells (ASC) were quantifi  ed by ELISPOT. (H and I) Fyn−/− mice exhibit a 
productive humoral response to a T-dependent antigen, SRBCs. Data 
represent two independent experiments (n = 4–5 mice/time point/group). 
(H) GC development evaluated by gating on B220+IgDlo cells and 
staining for FashiGL-7hi expression. (I) SRBC-specifi  c antibody response 
evaluated by ELISA 30 d after immunization. Fyn−/− mice are on a mixed 
129/Sv × C57BL/6 background. Controls from 129/Sv and C57BL/6 
strains are shown.1562  REGULATION OF HUMORAL IMMUNITY BY SAP | Cannons et al.
Figure 8.  Reexpression of SAP or SAP-R78A rescued aberrant 
CD40L and ICOS expression. SAP-defi  cient AND CD4 cells were recon-
stituted with WT SAP, SAP-R78A, or the Migr control vector. WT AND CD4 
cells were reconstituted with Migr. Cells were restimulated with 100 nM 
PCC-pulsed P13.9 cells. Data represent four independent experiments. 
(A) SAP protein expression confi  rmed by immunoblot. (B and C) Expression 
of either WT SAP or SAP-R78A reduced basal and activated CD40L mRNA 
expression. RNA was isolated after stimulation with peptide-pulsed P13.9 
APCs and subject to (B) RT-PCR and (C) real-time quantitative PCR analysis. 
(D and E) SAP and SAP-R78A, but not Migr control, improved CD40L kinetics 
and ICOS up-regulation in reconstituted SAP-defi  cient cells. Flow cytometric 
analysis (gated on CD4+GFP+ cells) of CD40L (top), ICOS (middle), and OX40 
(bottom) expression. (E) Overlaid data from the 24-h time point. Filled histo-
grams represent unstimulated cells.
  humoral defects in SAP−/− mice. The same scenario is also 
likely to be true in XLP because exogenous IL-10 only 
partially rescued antibody production in vitro (17). Such ob-
servations are consistent with phenotypes of IL-4−/− mice, 
which mainly aff  ect specifi  c Ig isotypes (31).
Consistent with the cytokine-independent T cell–intrin-
sic defect in humoral immunity, CD4 cells reconstituted with 
either WT SAP or a SAP mutant that aff  ects Fyn recruitment 
to SLAM (R78A) were able to improve GC formation, anti-
body production, and long-lived plasma cell development in 
a SAP−/− host (Fig. 7). Although we cannot exclude some 
residual Fyn binding with the SAP-R78A mutant, retroviral 
reexpression of this mutant failed to improve Th2 cytokine 
production (13), yet it rescued humoral responses. Consistent 
with our SAP-R78A observations, Fyn−/− mice are also able 
to form GCs upon immunization, despite defects in TCR-
induced Th2 cytokine production (13). Thus, SAP-mediated 
regulation of Th2 cytokine production and humoral immunity JEM VOL. 203, June 12, 2006  1563
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may involve distinct pathways. Such eff  ects may result from 
other potential interactions of SAP with Src family tyrosine 
kinases, such as Lck in addition to Fyn (32), or alternate 
mechanisms of SAP signaling, such as competition with 
phosphatases for SLAM-related receptors (5, 6).
It is therefore relevant that SAP-defi  cient CD4 cells show 
aberrant temporal regulation of two key cell surface markers, 
CD40L and ICOS, required for B cell help. Although the 
increased CD40L expression on SAP-defi  cient CD4 cells 
may seem paradoxical, administration of an agonist anti-
CD40 antibody has been shown to induce a pattern of extra-
follicular B cell diff  erentiation while abolishing GC formation 
and memory B cell generation in a T-dependent response 
(20, 21). Thus, CD40L expression requires tight regulation 
to generate appropriate humoral responses.
The expression of CD40L on T cells is complex, under-
going an early phase with a rapid induction attributed to 
TCR regulation that is quickly downmodulated and a later 
phase regulated partially through the actions of cytokines (22, 
23). Although sCD40L levels are in part down-regulated by 
interactions with CD40 (33), the mechanisms by which ex-
pression is controlled remain poorly understood. We provide 
evidence that SAP-mediated pathways have a profound im-
pact on CD40L mRNA levels, even before cell activation, 
when sCD40L expression is still quite low. In addition, 
SLAM ligation plays a novel role in regulating the early phase 
of sCD40L expression in a SAP-dependent fashion that is in-
dependent of its eff  ects on mRNA. Whether these eff  ects are 
due to SLAM’s eff  ects on adhesion or other signaling path-
ways is not known. Both WT and SAP-defi  cient AND CD4 
cells down-regulated TCR expression comparably in the 
presence of peptide-pulsed APCs as well as SLAM-expressing 
APCs, suggesting that at least some receptor endocytosis 
pathways are not aff  ected (Fig. S6, available at http://www.
jem.org/cgi/content/full/jem.20052097/DC1). Although 
naive T cells do express SLAM, SLAM is rapidly up-regu-
lated (within 3–6 h) in response to TCR stimulation and re-
mains high for several days. Conversely, in murine cells SAP 
expression is down-regulated 24 h after T cell stimulation 
(25). It is therefore intriguing that the eff  ects of SLAM on 
sCD40L expression are greatest at 3–12 h after stimulation, a 
time when both SLAM and SAP are expressed at high levels. 
Our data thus provides evidence for a new role for SLAM in 
T cell activation as well as insight into the dynamic regulation 
of CD40L expression.
Whether the increased sCD40L expression directly con-
tributes to the defect in long-term antibody production is 
diffi   cult to confi  rm in vivo. The reported eff  ects of CD40 
overstimulation suggest that it should lead to increased early 
antibody production and increased numbers of early plasma 
cells; however, this is not observed in SAP−/− mice. It is 
therefore relevant that both XLP patients and SAP−/− mice 
show decreased and delayed ICOS expression. Both ICOS 
defi  ciency and heterozygosity are associated with defects in 
GC formation and antibody production (34–36), suggesting 
that B cells are sensitive to levels of surface ICOS. Thus, to-
gether, the extent of ICOS up-regulation and the duration of 
sCD40L expression may have important biological conse-
quences for balancing the generation of GCs and B cell ter-
minal diff  erentiation. Indeed, the rescue of both ICOS and 
CD40L expression as well as humoral immunity by SAP-
R78A suggests a major link between these phenotypes. 
However, although both the impaired ICOS up-regulation 
and the prolonged CD40L expression may prevent eff  ective 
GC formation, the impairment of both early and late anti-
body levels suggests the ICOS defect in SAP−/− mice may 
play a more dominant role in the humoral phenotype.
Recently, a distinct subset of T cells, known as T follicu-
lar helpers, has been described, which provide help for GC 
diff  erentiation and express high levels of SAP, SLAM, CD84, 
and ICOS mRNA (37, 38). A recently described mutation in 
the gene roquin results in increased GC development with 
excessive T follicular helpers displaying elevated ICOS ex-
pression (38). Roquin is a RING-type E3 ubiquitin ligase 
containing a CCCH zinc fi  nger domain found in RNA bind-
ing proteins (38). SAP mRNA contains AUUUA sequences 
in the 3′ UTR that are targeted for ubiquitin-dependent 
degradation by RNA binding proteins such as AUF1 and 
HuR (39). It is intriguing to speculate that Roquin may help 
regulate degradation of SAP and/or ICOS mRNA and 
thereby GC formation.
Our results provide new insight into the nature of the T 
cell–intrinsic defects that aff  ect antibody responses in SAP−/− 
mice. Which SAP-associated receptors are responsible for 
these phenotypes, what the Fyn-independent signaling path-
ways downstream of SAP are, and how these phenotypes are 
aff  ected by T cell– and B cell–intrinsic defects remain impor-
tant questions. Nonetheless, the examination of SAP−/− mice 
underscores both the extent and importance of these humoral 
defects, as well as the potential role of Ig therapy for the treat-
ment of XLP patients.
MATERIALS AND METHODS
Mouse strains and reagents. SAP−/− mice (7) were backcrossed to 
C57BL/6J for 8–10 generations and maintained in sterile microisolator cages 
on autoclaved water and food, according to institutional guidelines. AND 
transgenic, RAG2−/−, and Fyn−/− mice were from The Jackson Laboratory, 
and OT-II transgenic mice were from Taconic. All the animals were housed 
and treated within published guidelines of humane animal care, and all pro-
cedures were performed according to National Human Genome Research 
Institute (NHGRI) Animal Care and Use Committee–approved protocols 
for animal research. The P13.9 fi  broblast cell line expressing I-Ek, CD80, 
and ICAM (40) as well as the SLAM-expressing variant were described pre-
viously (13). PCC peptide was purchased from SynPep.
Immunizations. Mice were injected i.p. with 100 μg of either NP-KLH 
or NP-OVA (Biosearch Technologies Inc.) in Ribi (Fisher Scientifi  c). Mice 
were injected i.p. with 2.5 × 108 SRBCs (Colorado Serum) in 0.2 ml HBSS. 
For T-independent responses, mice were immunized with 100 μg NP-LPS 
(Biosearch Technologies Inc.) in 0.2 ml HBSS.
Adoptive transfer. OT-II CD4 lymphocytes were purifi  ed via negative 
selection from lymph nodes and spleens as described previously (13). In vitro 
Th1 and Th2 diff  erentiation has been described (13). 3–5 × 106 CD4 cells 
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i.v. tail vein injection, and 24 h later, mice were immunized i.p. with NP-
OVA. For RAG2−/− reconstitution experiments, CD4 T cells were purifi  ed 
from spleens and lymph nodes via negative selection and sorted for CD-
44loCD62Lhi naive cells. Splenic B cells were isolated via negative selection 
and sorted for CD19+ cells. 5 × 106 naive CD4 T cells and 10 × 106 CD19 
B cells from WT or SAP−/− mice were transferred i.v. into RAG2−/− hosts.
Response to S. mansoni eggs. Groups of mice were i.p. primed with 5,000 
S. mansoni eggs, i.v. challenged with 5,000 eggs 2 wk later, and killed after 
8 d. Histology was performed as described previously (41). Single cell suspen-
sions from either the mediastinal lymph nodes or spleens were cultured at 
3 × 106/ml and 5 × 106/ml, respectively, with 20 μg/ml SEA.
Plasma cell ELISPOT. Goat anti–mouse IgG+M+A (Caltag Laborato-
ries) was used to capture antibody for total antibody-secreting cell ELISPOTs. 
Plates were blocked with RPMI 10% FCS, and bone marrow cells were 
added to the plate in threefold serial dilutions in RPMI 10% FCS and incu-
bated at 37°C for 5 h. Biotinylated goat anti–mouse IgGγ (Caltag Laborato-
ries) followed by streptavidin–horseradish peroxidase (Vector Laboratories) 
was used for detection. AEC was used for spot development. Plates were 
scanned by an ImmunoSpot Analyzer (Cellular Technology Ltd).
ELISA. 96-well fl  at-bottom Immuno Plates (Nunc) were coated overnight at 
4°C with [NP-(3)-BSA] or [NP-(30)-BSA] (2.5 μg/well; Biosearch Technolo-
gies Inc.) in PBS. For SRBC immunization, plates were coated overnight at 
4°C with SRBCs. Peroxidase-conjugated goat antibody specifi  c for total mouse 
IgG (Jackson ImmunoResearch Laboratories) IgG1, IgG2b, IgG3 (Southern-
Biotech), or IgG2a (Zymed Laboratories) was used to detect antibodies, and 
ABTS solution (KPL) was used as a developing substrate. Levels of SEA-  specifi  c 
antibody were determined by ELISA as described previously (42).
Flow cytometry and microscopy. All antibodies used for were from 
BD Biosciences, with the exception of anti-IgD (SouthernBiotech), SLAM 
(Biolegend), and PNA (Vector Laboratories). Samples stained for BrdU 
were washed in PBS, resuspended, fi  xed, and stained according to the 
  manufacturer’s instructions (BD Biosciences). Data analysis was performed 
using Flojo or CellQuest software. GCs were identifi  ed on 7-μM OCT-
embedded frozen sections using anti–GL-7–FITC, CD3-biotin, CD4-bio-
tin, CD8-biotin, IgD-biotin, and sheep anti–mouse IgD (The Binding Site). 
Secondary antibodies included streptavidin-Alexa568 (Invitrogen), anti–
sheep-Cy5, and anti–rat AMCA (Jackson ImmunoResearch Laboratories).
Retroviral transduction and cytokine production. CD4 cells were ret-
rovirally reconstituted with a vector control (Migr), hSAP, or SAP R78A 
(provided by K. Nichols, University of Pennsylvania, Philadelphia, PA) as 
described previously (13). Cytokines were detected by ELISA (R&D Sys-
tems). Intracellular cytokine analyses were performed on splenic and/or 
lymph node cultures as described previously (41).
RT and quantitative PCR. RNA was isolated with Trizol (Invitrogen 
Life Technologies). For RT-PCR, PCR amplifi  cation was performed for 35 
cycles. For RT and quantitative PCR analysis, RNA was added directly to 
one-step quantitative RT-PCR reactions (Invitrogen Life Technologies) as 
described previously (13). The following primers were used: for RT-PCR: 
CD40L forward primer: A  A  G  T  C  G  A  C  A  G  C  G  C  A  C  T  G  T  T  C  A  G  A  G  T  , CD40L 
reverse primer: C  G  G  A  A  T  T  C  A  G  T  C  A  G  C  A  T  G  A  T  A  G  A  A  A  C  ; and for quan-
titative PCR: CD40L forward primer: C A  A  A  T  T  G  C  A  G  C  A  C  A  C  G  T  T  G  T  A-
A  G  , CD40L reverse primer: T  C  A  A  G  C  A  T  T  A  C  C  A  A  G  T  T  G  C  T  T  T  T  C  , and 
CD40L probe FAM-C  A  G  C  A  T  C  C  G  T  T  C  T  A  C  A  G  T  G  G  G  C  C  A  A  -BHQ1.
Online supplemental material. Fig. S1 demonstrates that SAP−/− mice 
fail to form GCs after immunization with SRBCs. Fig. S2 shows that WT 
antigen-specifi  c CD4 cells rescued antibody production in the SAP−/− host. 
Fig. S3 is a direct comparison of WT and SAP-defi  cient B cells in the 
RAG2−/− transfer model. Fig. S4 shows the mean fl  uorescence intensity of 
sCD40L and SLAM. Fig. S5 demonstrates that SLAM-expressing P13.9 
APCs have no detectible impact on the expression or mean fl  uorescence in-
tensity of ICOS on WT AND or SAP-defi  cient AND cells. Fig. S6 depicts 
TCR down-regulation in WT and SAP-defi  cient AND cells stimulated 
with peptide-pulsed and SLAM-expressing APCs.
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